

Get
A2

71. (New) A nonhuman transgenic embryo, fetus, or animal that is heterozygous for a targeted mutation in a GNK polypeptide having the sequence SEQ ID NO:4.

72. (New) A nonhuman GNK-deficient embryo, fetus, or animal produced by crossing heterozygous animals of claim 71.

73. (New) A cell from the embryo, fetus, or animal of claim 71.

74. (New) A cell from the embryo, fetus, or animal of claim 72.

75. (New) An antibody or fragment thereof which binds specifically to a polypeptide according to claim 61.

76. (New) The antibody or fragment of claim 75 wherein the antibody is a polyclonal antibody.

77. (New) The antibody or fragment of claim 75 wherein the antibody is a monoclonal antibody.

REMARKS

Applicants have amended the first section of the specification to update the cross-reference to related applications. A marked up version of the replacement section is shown in the Appendix entitled "VERSION WITH MARKINGS TO SHOW CHANGES."

Applicants have cancelled claims 1-52 and added claims 53-77. No new matter has been added.

Claims 1-5, 51, and 52 have been rewritten as claims 53-57. Claims 53-57 are supported by claims 1-5, 51, and 52 and throughout the specification, in particular, at page 13, line 6 to page 17, line 10, at page 9, lines 5-29, at page 36, lines 5-7, and at page 10, line 20 to page 12, line 16. Claim 58 is newly added, and is supported throughout the

specification and, in particular, at page 12, line 17 to page 13, line 5, and at page 21, line 14 to page 27, line 6.

Claims 6-9 have been rewritten as claims 59-63. Claims 59-63 are supported by claims 6-9 and throughout the specification, in particular, at page 12, line 17 to page 13, line 5, at page 21, line 14 to page 27, line 6, and at page 15, line 11 to page 21, line 13.

Claims 31-33, 35-38, 41-44, and 46-48 have been rewritten as claims 64-77. Claims 64-77 are supported by claims 31-33, 35-38, 41-44, and 46-48 and throughout the specification.

Applicants respectfully submit that pending claims 53-77 are in condition for allowance. If a telephone interview would be helpful in advancing the prosecution of this application, Applicants' attorney invites the Examiner to contact her at the number provided below.

Law Department
Immunex Corporation
51 University Street
Seattle, Washington 98101
Telephone: (206) 389-4079
Facsimile: (206) 233-0644

Respectfully submitted,



Julie K. Smith, Ph.D.
Attorney for Applicants
Registration No. 38,619

APPENDIX
VERSION WITH MARKINGS TO SHOW CHANGES

In the Specification

The following is a marked up version of the section at page 1, lines 3-5.

CROSS-REFERENCE TO RELATED APPLICATION

~~The present application claims the benefit of U.S. Provisional Application No. 60/113,003, filed December 18, 1998, which is hereby incorporated by reference.~~

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of pending International Application No. PCT/US99/29989, filed 17 December 1999, which was published under PCT Article 21 (2) on 22 June 2000, in English, as WO 00/36097, which claims the benefit of U.S. Provisional Application Serial No. 60/113,003, filed 18 December 1998, now abandoned. International Application No. PCT/US99/29989 and U.S. Provisional Application Serial No. 60/113,003 are incorporated herein by reference.